Current treatment protocol for HIV infection consists of highly active antiretroviral therapy, or HAART.
Current HAART options are combinations of at least three drugs belonging to at least two or classes of antiretroviral agents.
Typically, these classes are two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Entry or fusion Inhibitors provide treatment options for patients who are infected with viruses already resistant to common therapies
Antiretroviral drugs |
Examples |
Nucleoside reverse transcriptase inhibitors |
Zidovudine, Lamivudine, Didanosine, Stavudine, Zalcitabine |
Non-nucleoside reverse transcriptase inhibitors |
Nevirapine, Efavirenz, Delaverdin |
Protease inhibitors |
Indinavir, Ritonavir, Saquinavir, Lopinavir |
Fusion or entry inhibitors |
Enfuvirtide |
Nucleotide inhibitors |
Tenfovir |
Integrase inhibitors |
Raltegravir |
Chemokine co-receptor antagonists |
Maraviroc |
The current recommended treatment for HIV/AIDS
Typically, these classes are two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Antiviral drug |
Class |
Adverse effects |
Comments |
Nucleoside Reverse Transcriptase Inhibitors |
Zidovudine |
Anemia, neutropenia, fatigue, malaise, headache, myalgia, myopathy, hyperpigmentation of skin and nails |
Twice-daily dosing preferred over thrice-daily dosing. Reduce the dose in renal disorders. |
|
Lamivudine |
Headache, dry mouth. |
Adverse effects occur infrequently. Active against hepatitis B virus |
|
Didanosine |
Pancreatitis, peripheral neuropathy, diarrhea |
Concomitant alcohol use may increase risk of pancreatitis. Increased risk of peripheral neuropathy when combined with Stavudine. |
|
Abacavir |
Hypersensitivity syndrome (fever, myalgia, malaise, nausea, vomiting, symptoms suggestive of upper respiratory tract infection, anorexia) |
In case of hypersensitivity syndrome, Abacavir must be discontinued permanently. |
Non nucleoside Reverse Transcriptase Inhibitors |
Nevirapine |
Elevation in liver function test, hepatitis, liver failure |
Hepatotoxicity may be life threatening. Monitor liver tests closely for the first 16 weeks of treatment. |
|
Efavirenz |
Abnormal liver function test, hyerlipidemia |
Nervous system symptoms are common; severity usually decreases within 2-4 weeks. |
Protease Inhibitors |
Lopinavir/Ritonavir |
Diarrhea, nausea, vomiting , dyslipidemia, elevations in liver function tests, taste perversion, circum oral or perioral numbness.
|
Alcohol in the oral solution may cause disulfiram-like reaction. |
|
Indinavir |
Kidney stones, hyperuricemia, flank pain |
Patients should drink at least 1.5 liters of fluid daily. |
|
Saquinavir |
Nausea, vomiting, and diarrhea, oral ulcerations |
Must be used in combination with low-dose Ritonavir. |
Fusion inhibitors |
Enfuvirtide |
Reduces the blood counts, increases the risk of pneumonia, allergic reaction at the site of injection. |
|